Free Trial

Craneware plc (LON:CRW) Insider Sells £9,322,500 in Stock

Craneware logo with Medical background

Craneware plc (LON:CRW - Get Free Report) insider Keith Neilson sold 423,750 shares of the company's stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of GBX 2,200 ($28.77), for a total transaction of £9,322,500 ($12,191,055.32).

Craneware Stock Down 4.5 %

Shares of CRW traded down GBX 105 ($1.37) during trading hours on Wednesday, reaching GBX 2,215 ($28.97). The company's stock had a trading volume of 2,732,031 shares, compared to its average volume of 91,903. The company has a 50 day moving average of GBX 2,317.98 and a two-hundred day moving average of GBX 2,268.97. The company has a quick ratio of 1.00, a current ratio of 0.63 and a debt-to-equity ratio of 12.22. The firm has a market cap of £782.34 million, a price-to-earnings ratio of 9,008.00 and a beta of 0.28. Craneware plc has a 1-year low of GBX 1,340.71 ($17.53) and a 1-year high of GBX 2,509.20 ($32.81).

Craneware Increases Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Thursday, November 28th will be paid a GBX 16 ($0.21) dividend. This represents a yield of 0.77%. The ex-dividend date is Thursday, November 28th. This is a positive change from Craneware's previous dividend of $13.00. Craneware's dividend payout ratio is currently 11,600.00%.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank reiterated a "buy" rating and set a GBX 2,700 ($35.31) price target on shares of Craneware in a report on Tuesday, September 3rd.

Check Out Our Latest Analysis on CRW


About Craneware

(Get Free Report)

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors.

See Also

→ Forget Trump and Kamala (From Investors Alley) (Ad)

Should you invest $1,000 in Craneware right now?

Before you consider Craneware, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Craneware wasn't on the list.

While Craneware currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Is Palantir Heading for a $50 Price Target?
Rate Cuts Fuel Volatility: How Long Could it Last?
SMCI Stock: Is a Rebound Coming?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines